Riley Reduces Lantheus Holdings (LNTH) PT to $109, Maintains Buy Rating

Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued stocks to buy and hold for 3 years. Earlier on June 23, B. Riley analyst Yuan Zhi reduced the firm’s price target on Lantheus from $122 to $109, while maintaining a Buy rating on the shares. The adjustment was made following the company’s Q1 2025 financial update.

In Q1 2025, the company announced consolidated net revenue of $372.8 million, which was a 0.8% increase year-over-year. PYLARIFY sales were $257.7 million and remained flat compared to the prior year. Precision Diagnostic revenue was $104.4 million, also flat year-over-year. DEFINITY sales increased by 3.5% to $79.2 million, while TechneLite revenue decreased by 9.2% to $19.7 million due to a brief supply issue.

Riley Reduces Lantheus Holdings (LNTH) PT to $109, Maintains Buy Rating

An oncologist discussing an anti-PD1 therapy option with a patient.

Lantheus experienced a decrease in profitability in Q1. Gross profit margin fell by 180 basis points to 67%. Operating expenses increased to 28.3% of net revenue, 1.47% higher than the prior year. As a result, operating profit decreased by 7.1% to $144.3 million. As of the end of Q1 2025, cash and cash equivalents stood at $938.5 million.

Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

While we acknowledge the potential of LNTH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LNTH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.